A Phase 1/2 interventional study of Ibrutinib and Nivolumab in Hematologic Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 18 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing nivolumab in Hematologic Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Nivolumab · Hematologic Neoplasms.
Among the 11 studies testing nivolumab in Hematologic Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is the only one in phase 1/2, and was the 2nd registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →1 of the 11 studies testing nivolumab in Hematologic Neoplasms is open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6
First in 2013; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 37 across the 11 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
14 studies in Hematologic Neoplasms by Johnson & Johnson: 2 open now, 5 under way, none of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 14 studies in Hematologic Neoplasms by Johnson & Johnson, this one is the only one that started in 2015, is one of 2 in phase 1/2, and was the 7th registered.
Johnson & Johnson’s Hematologic Neoplasms studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing nivolumab in Hematologic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 14 in Hematologic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and to establish the recommended phase 2 dose (RP2D) for the combination of ibrutinib and nivolumab in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), follicular cell lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Once the dose is optimized, the combination will be assessed for Pharmacokinetics, Pharmacodynamics, and preliminary efficacy, further safety in participants with CLL/SLL, FL or DLBCL and in participants with Richter syndrome.
This is an open-label study, which consists of Part A (Dose Optimization Cohorts) and Part B (Expansion Cohorts). Part A consists of two dose optimization cohorts (cohort A1 and cohort A2) will determine the RP2D for the combination based on safety, pharmacokinetic, and pharmacodynamic assessments in participants with relapsed/refractory CLL/SLL or B-cell non-Hodgkin lymphoma (B-NHL). Part B consists 3 participant populations to further evaluate the safety and clinical activity of ibrutinib in combination with nivolumab: Cohort B1 (participants with CLL/SLL with del 17p or del 11q), Cohort B2 (participants with FL), Cohort B3 (participants with DLBCL) and Cohort B4 (participants with Richter syndrome). Part A and B will consist of Screening Period (28 days before enrollment), Treatment Period and Follow up Period (every 3 months until death or the end of study). Participants will receive nivolumab intravenously (Day 1 of every cycle) and ibrutinib orally once daily on a 14-day cycle. Efficacy will primarily be evaluated by International Workshop on Chronic Lymphocytic Leukemia (IWCLL) and International Working Group (IWG) for lymphoma guidelines. Participants' safety will be monitored throughout the study. Further exploration of pharmacokinetic/pharmacodynamic and biomarker information will be assessed throughout the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Nivolumab
Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Nivolumab
Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Nivolumab
Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Nivolumab
Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Nivolumab
Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Nivolumab
Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
Also known as: JNJ54179060
Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
Also known as: BMS-936558
Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008: Disease Cohort
ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/L, platelets \>100\*10\^9/L, Hgb \>11 g/dL and absolute lymphocyte count \<4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- \>=50% drop in lymphocyte count from baseline or \<=4.0\*10\^9/L with following: \>=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, \>=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils \>1.5\*10\^9/L, Platelets\>100000/mcL and Hgb\>11 g/dL or \>=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only.
Time frame: Up to 6 years 11 months
Overall Response Rate (ORR) as Assessed Non-Hodgkin Lymphoma (NHL), Cheson 2014: Disease Cohort
ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is \>= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) \>= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only.
Time frame: Up to 6 years 11 months
Percentage of Participants With Treatment-emergent Adverse Event (TEAEs): Study Cohort
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent.
Time frame: Up to 6 years 10 months
Duration of Response (DoR): Study Cohort
DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (\>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
Time frame: Up to 6 years 11 months
Duration of Stable Disease or Better: Study Cohort
Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
Time frame: Up to 6 years and 11 months
Progression-free Survival (PFS): Study Cohort
PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
Time frame: Up to 6 years 11 months
Overall Survival (OS): Study Cohort
OS was defined as duration from the date of first dose of study drug to the date of the participant's death.
Time frame: Up to 6 years 11 months
Percentage of Participants With Lymphoma-related Symptoms: Study Cohort
Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other.
Time frame: Up to 6 years 11 months
| Milestone | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 36 | 35 | 39 | 20 |
| Treated (safety analysis set) | 7 | 7 | 35 | 35 | 37 | 20 |
| Completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Not completed | 7 | 7 | 35 | 35 | 39 | 20 |
| Withdrew: Death | 4 | 4 | 22 | 12 | 20 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 3 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 5 | 7 | 8 | 3 |
| Withdrew: Other | 1 | 2 | 6 | 13 | 10 | 3 |
ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/L, platelets \>100\*10\^9/L, Hgb \>11 g/dL and absolute lymphocyte count \<4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- \>=50% drop in lymphocyte count from baseline or \<=4.0\*10\^9/L with following: \>=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, \>=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils \>1.5\*10\^9/L, Platelets\>100000/mcL and Hgb\>11 g/dL or \>=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only.
| Percentage of Participants | Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) |
|---|---|
| Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008: Disease Cohort | 63.3 |
ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is \>= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) \>= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only.
| Percentage of Participants | Ibrutinib and Nivolumab: Small Lymphocytic Lymphoma (SLL) | Ibrutinib and Nivolumab: Follicular Lymphoma (FL) | Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) | Ibrutinib and Nivolumab: Richter |
|---|---|---|---|---|
| Overall Response Rate (ORR) as Assessed Non-Hodgkin Lymphoma (NHL), Cheson 2014: Disease Cohort | 50.0 | 32.5 | 37.8 | 65.0 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent.
| Percentage of Participants | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Event (TEAEs): Study Cohort | 100 | 100 | 100 | 100 | 97.3 | 95.0 |
DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (\>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
| Months | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Response (DoR): Study Cohort | 11.5 (2.4 to 20.7) | NA (NA to NA) | 19.2 (9.4 to 19.4) | 10.2 (5.1 to 17.8) | NA (4.6 to NA) | 6.9 (1.3 to NA) |
Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
| Months | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Stable Disease or Better: Study Cohort | 24.8 (24.8 to 24.8) | 20.8 (20.8 to 20.8) | 17.38 (14.0 to 21.6) | 14.55 (12.7 to 20.4) | 14.1 (14.1 to 14.1) | — |
PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
| Months | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS): Study Cohort | 2.0 (1.1 to 24.8) | 9.1 (0.7 to 20.8) | 21.6 (12.0 to 21.6) | 7.6 (2.9 to 12.7) | 3.2 (2.1 to NA) | 5.0 (2.4 to NA) |
OS was defined as duration from the date of first dose of study drug to the date of the participant's death.
| Months | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Overall Survival (OS): Study Cohort | 12.4 (2.0 to 28.8) | NA (0.8 to NA) | NA (21.6 to NA) | NA (NA to NA) | 19.0 (7.7 to NA) | 10.3 (4.8 to NA) |
Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other.
| Percentage of Participants | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Lymphoma-related Symptoms: Study Cohort | 14.3 | 42.9 | 74.3 | 25.7 | 54.1 | 60.0 |
Collected over Up to 6 years 11 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 4/7 (57.1%) | 4/7 (57.1%) | 7/7 (100%) |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 4/7 (57.1%) | 3/7 (42.9%) | 7/7 (100%) |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 22/36 (61.1%) | 23/35 (65.7%) | 35/35 (100%) |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 12/35 (34.3%) | 15/35 (42.9%) | 35/35 (100%) |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 20/39 (51.3%) | 23/37 (62.2%) | 35/37 (94.6%) |
| Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 13/20 (65%) | 15/20 (75%) | 19/20 (95%) |
| Event | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/7 | 1/7 | 2/35 | 0/35 | 3/37 | 0/20 |
| Atrial FibrillationCardiac disorders | 1/7 | 0/7 | 1/35 | 0/35 | 1/37 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/7 | 0/7 | 0/35 | 1/35 | 1/37 | 0/20 |
| Oesophageal CompressionGastrointestinal disorders | 1/7 | 0/7 | 0/35 | 0/35 | 0/37 | 0/20 |
| Chest PainGeneral disorders | 1/7 | 0/7 | 0/35 | 1/35 | 0/37 | 0/20 |
| General Physical Health DeteriorationGeneral disorders | 1/7 | 0/7 | 1/35 | 0/35 | 0/37 | 0/20 |
| Multiple Organ Dysfunction SyndromeGeneral disorders | 0/7 | 1/7 | 0/35 | 0/35 | 0/37 | 1/20 |
| Bile Duct StoneHepatobiliary disorders | 1/7 | 0/7 | 0/35 | 0/35 | 0/37 | 0/20 |
| CholecystitisHepatobiliary disorders | 1/7 | 0/7 | 0/35 | 0/35 | 0/37 | 1/20 |
| BacteraemiaInfections and infestations | 1/7 | 0/7 | 0/35 | 1/35 | 0/37 | 0/20 |
| Event | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/7 | 1/7 | 13/35 | 12/35 | 12/37 | 5/20 |
| NeutropeniaBlood and lymphatic system disorders | 2/7 | 0/7 | 20/35 | 7/35 | 10/37 | 8/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/7 | 4/7 | 4/35 | 11/35 | 5/37 | 4/20 |
| FatigueGeneral disorders | 2/7 | 3/7 | 6/35 | 14/35 | 11/37 | 1/20 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 2/7 | 9/35 | 5/35 | 11/37 | 8/20 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/7 | 1/7 | 11/35 | 10/35 | 7/37 | 7/20 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/7 | 0/7 | 11/35 | 5/35 | 7/37 | 3/20 |
| PyrexiaGeneral disorders | 2/7 | 2/7 | 10/35 | 5/35 | 9/37 | 6/20 |
| RashSkin and subcutaneous tissue disorders | 1/7 | 1/7 | 6/35 | 8/35 | 11/37 | 4/20 |
| DyspepsiaGastrointestinal disorders | 2/7 | 1/7 | 3/35 | 3/35 | 2/37 | 0/20 |
The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab).
| Age, Continuous(years) | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61 ± 18.08 | 65.9 ± 13.96 | 64.3 ± 9.57 | 61.3 ± 11.94 | 59.2 ± 15.99 | 64.9 ± 11.19 | 62.2 ± 12.94 |
| Sex: Female, Male(Participants) | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 9 | 15 | 10 | 12 | 54 |
| Male | 3 | 3 | 26 | 20 | 27 | 8 | 87 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 3 | 0 | 0 | 4 |
| Not Hispanic or Latino | 7 | 7 | 34 | 31 | 35 | 20 | 134 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 2 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 0 | 1 | 2 | 0 | 5 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 5 | 35 | 33 | 34 | 20 | 134 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| AUSTRALIA | 0 | 0 | 2 | 1 | 8 | 1 | 12 |
| ISRAEL | 6 | 1 | 4 | 8 | 6 | 0 | 25 |
| POLAND | 0 | 0 | 18 | 6 | 6 | 10 | 40 |
| SPAIN | 1 | 3 | 5 | 6 | 2 | 4 | 21 |
| TURKEY | 0 | 0 | 6 | 6 | 8 | 1 | 21 |
| UNITED STATES | 0 | 3 | 0 | 8 | 7 | 4 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Feb 2022, 82 months.
Results were first posted in Jun 2023, 1 year 4 months after primary completion.
Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 82 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Nivolumab
Janssen Research & Development, LLC →